|
T.EXRO
|
Q4 revenue 0.9 mln, analyst $1.68 mln, 2023 $5.7 mln analyst expected $6.5...
|
|
T.EXRO
|
Full house again, won't sell any before Q1 earnings
|
|
T.EXRO
|
I will buy around 0.87, sell some if above 1.16 CAD, keeping the total shares...
|
|
T.EXRO
|
Not knowing which direction it will go
|
|
CRBU
|
Seem like a good stock, but definitely not popular
|
|
T.MDP
|
He is just trying to earn a living, there isn't any truth out of him
|
|
T.EXRO
|
Thanks for the advice, and I will take it. Exro will be the last penny stock...
|
|
T.EXRO
|
Just one, bbd-b.to, July 11, 2022, so went below $20 after reverse split...
|
|
T.EXRO
|
By the way, I love reverse split, it creates opportunities
|
|
T.EXRO
|
Always like another angle to look at things
|
|
T.EDT
|
But a raise is inevitable, there will be no other buyer except Baxter, but...
|
|
MCRB
|
Q4 earnings says as a result, we have confidence that we will ultimately...
|
|
MCRB
|
$225 mln due if target milestone reached for the $575 mln deal, $175 mln...
|
|
T.EXRO
|
$1.25 on UL certification
|
|
T.EXRO
|
Q4 2023 latest estimated revenue is $1.68 mln, I think they will quietly put...
|
|
T.MDP
|
Gene therapy needs time to verify the long term results, giving replacement...
|
|
T.MDP
|
FDA-approved gene therapies In November 2022, the Food and Drug...
|
|
T.MDP
|
How much they've spent on ixinity? A lot, https...
|
|
T.MDP
|
Cost per patient per year should be above $200k, while Gene therapy should be...
|
|
T.EXRO
|
Let's go above $1 first and shorters could start to work
|